Weiss Ratings Reaffirms “Sell (E+)” Rating for Beauty Health (NASDAQ:SKIN)

Beauty Health (NASDAQ:SKIN)‘s stock had its “sell (e+)” rating reissued by stock analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

SKIN has been the topic of a number of other research reports. TD Cowen raised their target price on Beauty Health from $2.00 to $2.50 and gave the stock a “hold” rating in a report on Monday, September 22nd. Stifel Nicolaus raised their target price on Beauty Health from $3.00 to $4.00 and gave the stock a “hold” rating in a report on Friday, August 1st. Wall Street Zen raised Beauty Health from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Cowen reaffirmed a “hold” rating on shares of Beauty Health in a research report on Monday, September 22nd. Finally, Roth Capital initiated coverage on Beauty Health in a research report on Friday, September 19th. They set a “buy” rating and a $3.50 price target on the stock. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Beauty Health currently has an average rating of “Hold” and an average price target of $2.81.

Beauty Health Price Performance

Beauty Health stock opened at $1.70 on Wednesday. The business’s 50-day simple moving average is $2.05 and its 200 day simple moving average is $1.70. The stock has a market cap of $215.59 million, a price-to-earnings ratio of -6.07 and a beta of 1.21. Beauty Health has a 12-month low of $0.78 and a 12-month high of $2.69. The company has a quick ratio of 4.15, a current ratio of 5.15 and a debt-to-equity ratio of 4.91.

Beauty Health (NASDAQ:SKIN) last issued its earnings results on Thursday, August 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. Beauty Health had a negative return on equity of 32.82% and a negative net margin of 6.13%.The firm had revenue of $78.20 million for the quarter, compared to analysts’ expectations of $74.67 million. Beauty Health has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, research analysts anticipate that Beauty Health will post -0.25 earnings per share for the current year.

Institutional Investors Weigh In On Beauty Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC acquired a new stake in Beauty Health in the 1st quarter valued at approximately $40,000. ProShare Advisors LLC grew its stake in Beauty Health by 45.5% in the second quarter. ProShare Advisors LLC now owns 23,447 shares of the company’s stock valued at $45,000 after purchasing an additional 7,336 shares in the last quarter. Simplicity Wealth LLC bought a new position in Beauty Health in the second quarter valued at approximately $49,000. Nuveen LLC bought a new position in Beauty Health in the first quarter valued at approximately $59,000. Finally, Police & Firemen s Retirement System of New Jersey grew its stake in Beauty Health by 87.5% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 31,408 shares of the company’s stock valued at $60,000 after purchasing an additional 14,653 shares in the last quarter. Institutional investors and hedge funds own 93.26% of the company’s stock.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.